Why Daxor Corporation’s (DXR) Stock Is Up 11.23%
As of Friday, July 17, Daxor Corporation’s DXR share price has surged by 11.23%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Daxor Corporation engages in medical instrumentation and biotechnology operations. It develops the BVA-100 Blood Volume Analyzer, an instrument that measures human blood volume, in conjunction with Volumex, a single-use radiopharmaceutical diagnostic injection and collection kit. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation operates as a subsidiary of Estate Of Joseph Feldschuh.
Commentary & Analysis
Why Daxor Corporation’s (DXR) Stock Is Up 5.75%
As of Monday, June 29, Daxor Corporation’s DXR share price has surged by 5.75%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Daxor Corporation’s (DXR) Stock Is Up 8.69%
As of Monday, June 15, Daxor Corporation’s DXR share price has surged by 8.69%, which has investors questioning if this is right time to sell.Michael Rose
Why Daxor Corporation’s (DXR) Stock Is Down 6.83%
As of Thursday, May 21, Daxor Corporation’s DXR share price has dipped by 6.83%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Daxor Corporation’s (DXR) Stock Is Down 5.47%
As of Tuesday, May 19, Daxor Corporation’s DXR share price has dipped by 5.47%, which has investors questioning if this is right time to buy.Jenna Brashear
Financial Summary
| Share Statistics | DXR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $58.4 | $422.9 | 16% |
|
| Shares Out (Mil) | 5.1 | 41.4 | 13% |
|
| Institutional Ownership | 52.4% | 83.6% | 36% |
|
| Float (Mil) | 2.9 | 34.9 | 8% |
|
| Beta | 0.04 | 0.88 | 7% |
|
| Avg Daily Volume (000s) | 2 | 409 | 9% |
|
| Price Change (52-week) |
(2.5%) | 66.3% | 42% |
|
| Growth | DXR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 11.9% | na |
|
| Net Income (5yr) | 49.3% | (5.9%) | 94% |
|
| EPS (5yr) | 44.4% | 10.4% | 91 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (14.9%) | (16.2%) | 53% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | DXR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $123 | na |
|
| Net Income (TTM) (Mil) | $9 | ($9) | 45% |
|
| EPS (TTM) | $1.812 | ($0.400) | 69% |
|
| Operating Cash Flow (TTM) (Mil) | $1 | ($3) | 33% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $22 | 0% |
|
| Enterprise Value (Q1) (Mil) | $66 | $418 | 19% |
|
| Valuation | DXR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.10 | 3.13 | 25% |
|
| P/E | 5.5 | 28.1 | 5% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.1 | 1.7 | 4% |
|
| Ratios | DXR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 58.7% | 96% |
|
| Net Margin | na | (6.9%) | na |
|
| ROA | 22.2% | (12.3%) | 97% |
|
| ROE | 22.5% | (12.3%) | 82% |
|
| Liabilities to Assets | 0.3% | 46.0% | 0% |
|
| F-Score | 5 | 4 | na |
|
Passing Stock Screens
As of 8/21/2026, from a list of 60 stock screening strategies,
GURU STRATEGY
Lynch Screen
Factors: Value
A strictly bottom-up approach, focusing on companies familiar to the investor.
| Performance Since Inception: | 10.1% |
| +/- S&P 500: | +2.6 |
